{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:05:45Z","timestamp":1759032345970,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U01FD005272","HHSF2232015101102C"],"award-info":[{"award-number":["U01FD005272","HHSF2232015101102C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2R01GM097618-04"],"award-info":[{"award-number":["2R01GM097618-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40264-017-0624-0","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:27:41Z","timestamp":1512178061000},"page":"363-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs"],"prefix":"10.1007","volume":"41","author":[{"given":"Ning","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Motiur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Peissig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard L.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. David","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"key":"624_CR1","unstructured":"World Health Organization. America\u2019s State of Mind Report 2011 [cited 2017 Feb 09]. \n                    http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js19032en\/\n                    \n                  ."},{"key":"624_CR2","unstructured":"BBC. Research. Therapeutic Drugs for Central Nervous System (CNS) Disorders: Technologies and Global Markets 2010 [cited 2017 Feb 09]. \n                    http:\/\/www.bccresearch.com\/market-research\/pharmaceuticals\/drugs-central-nervous-system-disorders-phm068a.html\n                    \n                  ."},{"issue":"4","key":"624_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/pds.872","volume":"13","author":"MA Fischer","year":"2004","unstructured":"Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004;13(4):207\u201314.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"11","key":"624_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.7326\/0003-4819-142-11-200506070-00006","volume":"142","author":"JS Haas","year":"2005","unstructured":"Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997\u20132000. Ann Intern Med. 2005;142(11):891\u20137.","journal-title":"Ann Intern Med."},{"key":"624_CR5","unstructured":"Express Scripts. Drug Trend Report 2016 [cited 2017 Feb 09]. \n                    https:\/\/lab.express-scripts.com\/lab\/drug-trend-report\n                    \n                  ."},{"issue":"6","key":"624_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.7326\/M13-2942","volume":"161","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med. 2014;161(6):400\u20137.","journal-title":"Ann Intern Med."},{"issue":"3","key":"624_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1001\/archinte.166.3.332","volume":"166","author":"WH Shrank","year":"2006","unstructured":"Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332\u20137.","journal-title":"Arch Intern Med."},{"issue":"2","key":"624_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","volume":"28","author":"WH Shrank","year":"2009","unstructured":"Shrank WH, Cox ER, Fischer MA, Mehta J, Choudhry NK. Patients\u2019 perceptions of generic medications. Health Aff. 2009;28(2):546\u201356.","journal-title":"Health Aff."},{"issue":"2","key":"624_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7326\/0003-4819-141-2-200407200-00011","volume":"141","author":"TA Brennan","year":"2004","unstructured":"Brennan TA, Lee TH. Allergic to generics. Ann Intern Med. 2004;141(2):126\u201330.","journal-title":"Ann Intern Med."},{"issue":"3","key":"624_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.seizure.2005.12.010","volume":"15","author":"P Crawford","year":"2006","unstructured":"Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs?: a review of issues. Seizure. 2006;15(3):165\u201376.","journal-title":"Seizure."},{"issue":"6","key":"624_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1755-5949.2010.00210.x","volume":"17","author":"JE Desmarais","year":"2011","unstructured":"Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther. 2011;17(6):750\u201360.","journal-title":"CNS Neurosci Ther."},{"key":"624_CR12","first-page":"293","volume":"15","author":"AS Kesselheim","year":"2015","unstructured":"Kesselheim AS, Darrow JJ. Hatch\u2013Waxman turns 30: do we need a re-designed approach for the modern era. Yale J Health Pol\u2019y L Ethics. 2015;15:293.","journal-title":"Yale J Health Pol\u2019y L Ethics."},{"issue":"2","key":"624_CR13","first-page":"585","volume":"71","author":"SD Danzis","year":"2003","unstructured":"Danzis SD. The Hatch\u2013Waxman act: history, structure, and legacy. Antitrust Law J. 2003;71(2):585\u2013608.","journal-title":"Antitrust Law J."},{"issue":"1","key":"624_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2125.2009.03399.x","volume":"68","author":"M Del Tacca","year":"2009","unstructured":"Del Tacca M, Pasqualetti G, Di Paolo A, Virdis A, Massimetti G, Gori G, et al. Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol. 2009;68(1):34\u201342.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"624_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40261-015-0374-7","volume":"36","author":"E Seoane-Vazquez","year":"2016","unstructured":"Seoane-Vazquez E, Rodriguez-Monguio R, Hansen R. Interchangeability, safety and efficacy of modified-release drug formulations in the USA: the case of opioid and other nervous system drugs. Clin Drug Investig. 2016;36(4):281\u201392.","journal-title":"Clin Drug Investig."},{"key":"624_CR16","unstructured":"U.S. Food and Drug Administration. Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies 2014 [cited 2017 Feb 09]. \n                    http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm322161.htm\n                    \n                  ."},{"key":"624_CR17","unstructured":"U.S. Food and Drug Administration. Methylphenidate Hydrochloride Extended Release Tablets (generic Concerta) made by Mallinckrodt and Kudco 2014 [cited 2017 Feb 09]. \n                    http:\/\/www.fda.gov\/drugs\/drugsafety\/ucm422568.htm\n                    \n                  ."},{"issue":"6","key":"624_CR18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","volume":"25","author":"G Borgheini","year":"2003","unstructured":"Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25(6):1578\u201392.","journal-title":"Clin Ther."},{"key":"624_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40801-015-0055-0","volume":"3","author":"GA Collett","year":"2016","unstructured":"Collett GA, Song K, Jaramillo CA, Potter JS, Finley EP, Pugh MJ. Prevalence of central nervous system polypharmacy and associations with overdose and suicide-related behaviors in Iraq and Afghanistan War veterans in VA care 2010\u20132011. Drugs Real World Outcomes. 2016;3:45\u201352.","journal-title":"Drugs Real World Outcomes."},{"issue":"15","key":"624_CR20","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2165\/00023210-200418150-00006","volume":"18","author":"RJ Valuck","year":"2004","unstructured":"Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder. CNS Drugs. 2004;18(15):1119\u201332.","journal-title":"CNS Drugs."},{"issue":"1\u20132","key":"624_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/cap.2006.16.25","volume":"16","author":"AD Mosholder","year":"2006","unstructured":"Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. J Child Adolesc Psychopharmacol. 2006;16(1\u20132):25\u201332.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"1","key":"624_CR22","first-page":"79","volume":"22","author":"M Mihanovic","year":"2010","unstructured":"Mihanovic M, Restek-Petrovic B, Bodor D, Molnar S, Oreskovic A, Presecki P. Suicidality and side effects of antidepressants and antipsychotics. Psychiatr Danub. 2010;22(1):79\u201384.","journal-title":"Psychiatr Danub."},{"issue":"1","key":"624_CR23","first-page":"13","volume":"8","author":"Z Rihmer","year":"2006","unstructured":"Rihmer Z, Gonda X. Suicide behaviour of patients treated with antidepressants. Neuropsychopharmacol Hung. 2006;8(1):13\u20136.","journal-title":"Neuropsychopharmacol Hung."},{"issue":"7488","key":"624_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/bmj.330.7488.396","volume":"330","author":"D Fergusson","year":"2005","unstructured":"Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.","journal-title":"BMJ."},{"issue":"3","key":"624_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1759-8893.2012.00093.x","volume":"3","author":"JE Lavigne","year":"2012","unstructured":"Lavigne JE, Au A, Jiang R, Wang Y, Good CP, Glassman P, et al. Utilization of prescription drugs with warnings of suicidal thoughts and behaviours in the USA and the US Department of Veterans Affairs, 2009. J Pharm Health Serv Res. 2012;3(3):157\u201363.","journal-title":"J Pharm Health Serv Res."},{"key":"624_CR26","unstructured":"Los Angeles Times. Generic drugs' hidden downside [cited 16 March 2017]. Available from: \n                    http:\/\/articles.latimes.com\/2007\/dec\/17\/news\/OE-WAX17\n                    \n                  ."},{"issue":"17","key":"624_CR27","first-page":"811","volume":"146","author":"A Vergouwen","year":"2002","unstructured":"Vergouwen A, Bakker A. Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCl hemihydrate. Ned Tijdschr Geneeskd. 2002;146(17):811\u20132.","journal-title":"Ned Tijdschr Geneeskd."},{"issue":"3","key":"624_CR28","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/YIC.0b013e328337910b","volume":"25","author":"HC Margolese","year":"2010","unstructured":"Margolese HC, Wolf Y, Desmarais JE, Beauclair L. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol. 2010;25(3):180\u20132.","journal-title":"Int Clin Psychopharmacol."},{"issue":"10","key":"624_CR29","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S0149-2918(01)80139-9","volume":"23","author":"R Mofsen","year":"2001","unstructured":"Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther. 2001;23(10):1720\u201331.","journal-title":"Clin Ther."},{"key":"624_CR30","unstructured":"U.S. Food and Drug Administration. What is FAERS 2016 [cited 2016 June 15]. \n                    http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm\n                    \n                  ."},{"issue":"7","key":"624_CR31","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796\u2013803.","journal-title":"Int J Med Sci."},{"key":"624_CR32","doi-asserted-by":"publisher","unstructured":"Hansen RA, Qian J, Berg RL, Linneman JG, Seoane-Vazquez E, Dutcher S, et al. Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug. Clin Pharmacol Ther. 2016. \n                    http:\/\/dx.doi.org\/10.1002\/cpt.591\n                    \n                  .","DOI":"10.1002\/cpt.591"},{"issue":"9","key":"624_CR33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","volume":"158","author":"WA Ray","year":"2003","unstructured":"Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915\u201320.","journal-title":"Am J Epidemiol."},{"key":"624_CR34","unstructured":"Activities MDfR. Standardised MedDRA Queries 2017 [cited 2017 June 25]. \n                    http:\/\/www.meddra.org\/how-to-use\/tools\/smqs\n                    \n                  ."},{"issue":"2","key":"624_CR35","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2105\/AJPH.2014.301957","volume":"105","author":"EP Finley","year":"2015","unstructured":"Finley EP, Bollinger M, No\u00ebl PH, Amuan ME, Copeland LA, Pugh JA, et al. A national cohort study of the association between the polytrauma clinical triad and suicide-related behavior among US Veterans who served in Iraq and Afghanistan. Am J Public Health. 2015;105(2):380\u20137.","journal-title":"Am J Public Health."},{"issue":"Suppl 1","key":"624_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/pds.2335","volume":"21","author":"JT Walkup","year":"2012","unstructured":"Walkup JT, Townsend L, Crystal S, Olfson M. A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):174\u201382.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"12","key":"624_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1176\/appi.ps.201200587","volume":"64","author":"GE Simon","year":"2013","unstructured":"Simon GE, Rutter CM, Peterson D, Oliver M, Whiteside U, Operskalski B, et al. Does response on the PHQ-9 depression questionnaire predict subsequent suicide attempt or suicide death? Psychiatr Serv. 2013;64(12):1195\u2013202.","journal-title":"Psychiatr Serv."},{"issue":"1","key":"624_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/appi.ajp.163.1.101","volume":"163","author":"M Olfson","year":"2006","unstructured":"Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101\u20138.","journal-title":"Am J Psychiatry."},{"issue":"20","key":"624_CR39","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","volume":"71","author":"E Faught","year":"2008","unstructured":"Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology. 2008;71(20):1572\u20138.","journal-title":"Neurology."},{"issue":"10","key":"624_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00228-008-0480-z","volume":"64","author":"NW van de Vrie-Hoekstra","year":"2008","unstructured":"van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997\u20132005\u2014a study from the Netherlands. Eur J Clin Pharmacol. 2008;64(10):1013\u201320.","journal-title":"Eur J Clin Pharmacol."},{"issue":"11","key":"624_CR41","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care."},{"issue":"11","key":"624_CR42","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","volume":"28","author":"J Almenoff","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28(11):981\u20131007.","journal-title":"Drug Saf."},{"issue":"8","key":"624_CR43","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1128\/AAC.48.8.2787-2792.2004","volume":"48","author":"SL Spruance","year":"2004","unstructured":"Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787\u201392.","journal-title":"Antimicrob Agents Chemother."},{"issue":"5","key":"624_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/cc2955","volume":"8","author":"V Bewick","year":"2004","unstructured":"Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis. Crit Care. 2004;8(5):389\u201394.","journal-title":"Crit Care."},{"issue":"3","key":"624_CR45","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","volume":"48","author":"F Andermann","year":"2007","unstructured":"Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48(3):464\u20139.","journal-title":"Epilepsia."},{"issue":"1","key":"624_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1345\/aph.1P389","volume":"45","author":"WH Shrank","year":"2011","unstructured":"Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31\u20138.","journal-title":"Ann Pharmacother."},{"issue":"8","key":"624_CR47","first-page":"8","volume":"23","author":"M Miller","year":"2007","unstructured":"Miller M. Questions & answers. I\u2019ve been taking Zoloft Recently, my pharmacist filled my prescription with a generic form of the drug. Does the brand name matter? Harv Ment Health Lett Harv Med Sch. 2007;23(8):8.","journal-title":"Harv Ment Health Lett Harv Med Sch"},{"issue":"2","key":"624_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/026988119801200212","volume":"12","author":"RM Lane","year":"1998","unstructured":"Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998;12(2):192\u2013214.","journal-title":"J Psychopharmacol."},{"issue":"5","key":"624_CR49","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cpt.81","volume":"97","author":"J Bohn","year":"2015","unstructured":"Bohn J, Kortepeter C, Mu\u00f1oz M, Simms K, Montenegro S, Dal Pan G. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97(5):508\u201317.","journal-title":"Clin Pharmacol Ther."},{"issue":"9","key":"624_CR50","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40264-017-0550-1","volume":"40","author":"Geetha Iyer","year":"2017","unstructured":"Iyer G, Marimuthu SP, Segal JB, Singh S. An algorithm to identify generic drugs in the FDA adverse event reporting system. Drug Saf. 2017;40(9):799\u2013808.","journal-title":"Drug Safety"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0624-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0624-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:58:06Z","timestamp":1589669886000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0624-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0624-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2017,12,2]]},"assertion":[{"value":"2 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"In the past 3\u00a0years, Richard A. Hansen has provided expert testimony for Daiichi Sankyo. Richard\u00a0Hansen and Jingjing\u00a0Qian also have received grant funding from US FDA Grant U01FD005272 and contract HHSF2232015101102C, and these grants are directly related to the general topic of this manuscript. Dr. Hansen also received funding from National Institute of Health grant 2R01GM097618-04, which is related to but did not directly fund this work. Ning Cheng, Md. Motiur Rahman, Yasser Alatawi, Jingjing Qian, Peggy L. Peissig, Richard L. Berg, and David Page have no conflicts of interest that are directly relevant to the content of this study. Views expressed in written materials or publications and by speakers do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was supported by the U.S. Food and Drug Administration through Grant U01FD005272 and contract HHSF2232015101102C. A National Institute of Health Grant 2R01GM097618-04 provided related support but did not directly fund this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study was approved by the Auburn University Institutional Review Board for research involving human subjects (protocol 14-465 EP1410).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}